Strategic Focus Target high-value cardiometabolic markets with a portfolio centered on gene and peptide therapies for congestive heart failure and type 2 diabetes, offering potential for partnership in late-stage development and outcomes-focused trials.

Clinical Advantage Leverage the single-dose durable gene therapy approach delivered to the heart as a differentiator for outpatients, presenting collaboration opportunities with hospital systems and payer programs seeking transformative cardiovascular solutions.

Leadership Prestige Capitalize on the founders’ and leadership team’s recognized expertise and VA-affiliated award history to open doors with research institutions, grant programs, and potential co-development discussions.

Strategic Partnerships Propose co-development, translational research, and translational/clinical advisory collaborations with mid-size biotech and contract research organizations aiming to expand gene therapy capabilities and accelerate timelines.

Funding & Validation Align outreach with potential investors and strategic partners highlighting revenue range and ongoing pipeline; present opportunities around preclinical to early-stage programs and potential follow-on funding rounds to fuel expansion.